Sobi receives orphan drug designation for Elocta in Switzerland
Swedish Orphan Biovitrum AB has received Orphan Drug Designation in Switzerland for its long acting haemophilia drug candidate Elocta (rFVIIIFc) developed for the treatment of haemophilia A. An orphan drug designation is to encourage the development of medicines for rare diseases and provides orphan status to drugs and biologics under development.
Haemophilia is an inherited condition that influences the blood's ability to clot. The most common type of the condition is haemophilia A, where people lack clotting factor FVIII. The symptoms can be mild to severe, depending on the level of clotting factor. People with haemophilia bleed for longer than usual and in severe haemophilia, internal bleeding around joints and muscles are frequent. This causes pain, stiffness and may lead to joint damage. Haemophilia A is a rare disease, occuring in 1 of 5.000 male births.
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents

Food from CO2 - Arkeon Biotechnologies, a Viennese startup, uses gas fermentation technology to convert CO2 into food products
Roche Applied Science Industrial Business” Now Is “Roche Custom Biotech
The Safe Transfer and Assay of Infectious Agents - Labcyte Awarded U. S. Patent for Transferring Liquids within Sealed Containers
American_Association_of_Colleges_of_Pharmacy
AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis
Sigma® Life Science and King's College London co-developing miRNA Target Identification Technology
Stress affects brain’s blood flow
European Commission authorizes EU-wide marketing and distribution of Biofrontera's Ameluz
